Paper39216548
YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
Li B and 11 others. Cancer Lett, 2024. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Papers, record 39216548. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39216548
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| beta Catenin | Major topic |
| Carcinoma, Pancreatic Ductal | Major topic |
| Deoxycytidine | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Gemcitabine | Major topic |
| Low Density Lipoprotein Receptor-Related Protein-1 | Major topic |
| Pancreatic Neoplasms | Major topic |
| Ribonucleoside Diphosphate Reductase | Major topic |
| Y-Box-Binding Protein 1 | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Antimetabolites, Antineoplastic | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Gene Expression Regulation, Neoplastic | |
| Mice, Nude | |
| Signal Transduction | |
| Tumor Suppressor Proteins | |
| Xenograft Model Antitumor Assays |
Source PubMed
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42957640 | Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glycolysis in pancreatic cancer. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42957640 | PubMed |
| 42698848 | YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance. | Front Immunol | 2026 | https://conductscience.org/library/papers/42698848 | PubMed |
| 42480704 | MOF promotes venous thromboembolism in lung cancer by activating the YBX1-MALT1-NF-κB-PAI-1 axis, possibly through histone crotonylation. | J Biol Chem | 2026 | https://conductscience.org/library/papers/42480704 | PubMed |
| 42312894 | Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer. | Wiley Interdiscip Rev Nanomed Nanobiotechnol | 2026 | https://conductscience.org/library/papers/42312894 | PubMed |
| 42278514 | Age- and Treatment-Specific TP53 and PI3K Alterations in Pancreatic Ductal Adenocarcinoma (PDAC) Revealed by Conversational Artificial Intelligence. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278514 | PubMed |
| 42158236 | Interplay of RNA m6A/m1A/m5C/m7G/ψ Regulators Predicting the Prognosis of Pancreatic Cancer. | FASEB Bioadv | 2026 | https://conductscience.org/library/papers/42158236 | PubMed |
| 42052571 | Epigenetic regulation in cancer chemoresistance and combined therapeutic strategies. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42052571 | PubMed |
| 41987290 | Uridine metabolism promotes lung adenocarcinoma progression by activating FBL transcription via YBX1. | J Transl Med | 2026 | https://conductscience.org/library/papers/41987290 | PubMed |
| 41513625 | RECQL4 promotes the malignant progression of lung adenocarcinoma through the YBX1/G3BP1-mediated NF-κB signaling pathway. | Cell Death Discov | 2026 | https://conductscience.org/library/papers/41513625 | PubMed |
| 41507134 | YBX1 orchestrates LDHA-mediated metabolic reprogramming and NF-κB activation to drive clear cell renal cell carcinoma progression. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41507134 | PubMed |
| 41444422 | SLC6A14-mediated glutamine promotes SYTL4-CXCL8 axis activation to drive gemcitabine resistance and immune evasion in pancreatic cancer. | Exp Mol Med | 2025 | https://conductscience.org/library/papers/41444422 | PubMed |
| 41131631 | USP21/YBX1/HIF1-α promotes the progression of prostate cancer. | J Transl Med | 2025 | https://conductscience.org/library/papers/41131631 | PubMed |
| 41070608 | Multifaceted functions of Y‑box binding protein 1 in RNA methylated modifications (Review). | Mol Med Rep | 2025 | https://conductscience.org/library/papers/41070608 | PubMed |
| 41029024 | YBX1 Enhances the Stability of TM4SF1 in an m5C-Dependent Manner to Promote Bladder Cancer Proliferation and Glycolysis. | Comb Chem High Throughput Screen | 2026 | https://conductscience.org/library/papers/41029024 | PubMed |
| 41025501 | YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas. | Neuro Oncol | 2026 | https://conductscience.org/library/papers/41025501 | PubMed |
| 40938464 | The functions and regulation of transcription factor YBX1 in cancers. | Mol Biol Rep | 2025 | https://conductscience.org/library/papers/40938464 | PubMed |
| 40814288 | The dual role of RNA-binding proteins: promotion of tumorigenesis, drug resistance, and emerging therapeutic targets. | Acta Biochim Biophys Sin (Shanghai) | 2025 | https://conductscience.org/library/papers/40814288 | PubMed |
| 40783393 | EPS8L2 drives colorectal cancer cell proliferation and migration via YBX1-dependent activation of G3BP2 transcription. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40783393 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| LRP1 | 4035 | PubTator's text mining | https://conductscience.org/library/genes/4035 | NCBI Gene |
| RRM1 | 6240 | PubTator's text mining | https://conductscience.org/library/genes/6240 | NCBI Gene |
| TCF3 | 6929 | PubTator's text mining | https://conductscience.org/library/genes/6929 | NCBI Gene |
| YBX1 | 4904 | PubTator's text mining | https://conductscience.org/library/genes/4904 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39216548
GET https://conductscience.org/api/papers/v1/39216548/authors